Open AccessOutcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
Author(s) -
Daniel E. Lage,
M. Dror Michaelson,
Richard J. Lee,
Joseph A. Greer,
Jennifer S. Temel,
Christopher J. Sweeney
Publication year - 2021
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-021-00389-2
Subject(s) - medicine , docetaxel , prostate cancer , hazard ratio , androgen deprivation therapy , adverse effect , oncology , cancer , randomized controlled trial , proportional hazards model , confidence interval
Most men who die of prostate cancer are older than 70 years. The ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) randomized men of all ages with metastatic hormone-sensitive prostate cancer (mHSPC) to receive androgen deprivation therapy (ADT) with or without docetaxel demonstrating an overall survival (OS) benefit for docetaxel.